Gyre Therapeutics, Inc., was incorporated in Delaware on March 7, 1997. The Company and its subsidiaries are biopharmaceutical companies focused on the development and treatment of small molecule therapies for organ fibrosis and inflammatory diseases. Through the successful development and launch of the product for the treatment of pulmonary fibrosis, the company has established a solid business foundation in China and has become a well-known player in the field of pulmonary fibrosis treatment. By expanding to the United States, the company is advancing a pipeline of products under development including F 351 (oxygenone) for liver fibrosis. The core of its strategy is to use marketed products to support late-stage development to address unmet medical needs in fibrosis and related inflammatory diseases. 

Gyre Therapeutics announced management participation in the Cantor Global Healthcare Conference and Morgan Stanley Healthcare Conference. The company's management will participate in fireside chats at both conferences, which will be webcast live and available on the company's website for 30 days after the event. Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on developing small-molecule therapeutics for organ fibrosis and inflammatory diseases. The company's subsidiary, Cullgen Inc., is a clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degrader and DAC therapies for critical conditions.

Gyre Therapeutics

Gyre Therapeutics to Present at Cantor Global Healthcare Conference, Morgan Stanley Healthcare Conference

Gyre Therapeutics (NASDAQ: GYRE) has reaffirmed its full-year 2026 revenue guidance of $100.50 million to $111.00 million, as outlined in its <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">recent first-quarter 2026 earnings report</a>. The company reported Q1 2026 revenue of $22.5 million, which marked <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">a modest increase compared</a> to the same period in 2025. However, the company also noted <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">a net loss of $9.9 million</a> for the quarter, driven by increased operating expenses and a decline in net income compared to the prior year.The reaffirmed guidance reflects a projected decline in revenue compared to 2025, when the company generated <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025">$116.6 million in full-year revenue</a>. This anticipated drop is attributed to a transition period in 2026, during which Gyre plans to prioritize regulatory activities, including <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">submission of a New Drug Application</a> (NDA) for its lead candidate, F351 (hydronidone), for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis. The NDA was submitted to China’s Center for Drug Evaluation (CDE) in March 2026 and has been <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">granted priority review status</a>.In addition to regulatory progress, Gyre completed <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">the acquisition of Cullgen Inc.</a> in May 2026, expanding its pipeline into inflammatory diseases and cancers. The acquisition is expected to <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">enhance long-term innovation capabilities</a> and diversify its therapeutic focus beyond fibrosis.Despite the anticipated revenue decline, the company remains focused on advancing its pipeline and strengthening its commercial portfolio. ETUARY™ (pirfenidone) remains a key revenue driver, while <a href="https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-first-quarter-2026-results-and">new launches such as Etorel™</a> and Contiva™ continue to contribute to sales. Looking ahead, Gyre’s strategic emphasis on regulatory milestones and pipeline expansion may influence its financial performance in the coming quarters.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cf1d7fd93ad1002.png" alt="Gyre Therapeutics affirms FY2026 revenue guidance of $100.50 mln-$111 mln">

Gyre Therapeutics affirms FY2026 revenue guidance of $100.50 mln-$111 mln

Gyre Therapeutics has appointed three new members to its Board of Directors, effective August 1, 2026. Yue Xiong, Ph.D. as Chief Scientific Officer, Maxwell Kirkby, and Claire Weston, Ph.D. will join the Board, expanding its scientific, clinical development, and cross-border biopharmaceutical operating expertise. The new appointments are expected to help Gyre advance its broad pipeline of products targeting various therapeutic areas, including fibrosis, cancer, inflammation, and pain.Gyre Therapeutics has appointed three new members to its Board of Directors, effective August 1, 2026, to strengthen its leadership in key therapeutic areas. Yue Xiong, Ph.D., has been named Chief Scientific Officer, while Maxwell Kirkby and Claire Weston, Ph.D., will join the Board. These appointments are expected to enhance Gyre’s scientific and operational capabilities, supporting the company’s <a href="https://www.gyretx.com/about/">development of therapies for fibrosis</a>, cancer, inflammation, and other diseases.Dr. Xiong brings extensive experience in biochemistry and biophysics, with a distinguished academic career spanning over three decades. He has published more than 200 peer-reviewed articles and holds two U.S. patents, reflecting his <a href="https://www.cullgen.com/yue-xiong">deep expertise in drug discovery</a> and development. His leadership is expected to bolster Gyre’s research initiatives, particularly in the area of targeted protein degradation, which the company acquired through its <a href="https://www.gyretx.com/science/">recent acquisition of Cullgen Inc.</a>.Maxwell Kirkby and Claire Weston are expected to contribute strategic and operational insights, particularly in cross-border biopharmaceutical development and commercialization. With Gyre’s expanding pipeline, including F351 for liver fibrosis and multiple targeted protein degrader candidates, the company is <a href="https://www.gyretx.com/science/">positioning itself to advance therapies</a> across multiple indications.The new appointments align with Gyre’s broader strategy to strengthen its leadership in both the United States and the People’s Republic of China, where it has a controlling interest in Gyre Pharmaceuticals. The company’s flagship product, ETUARY™ (pirfenidone capsule), has been a key driver of its commercial success in the PRC since <a href="https://www.gyretx.com/science/">its approval in 2011</a>.

Catalyst Biosciences

Gyre Therapeutics Appoints 3 New Board Members for Enhanced Expertise

Gyre Therapeutics appoints three new members to its board of directors

Gyre Therapeutics appoints three new members to its board of directors

• Cullgen Inc. reported a consolidated balance sheet of $X as of December 31, 2025.
• The related consolidated statements of comprehensive loss, redeemable convertible preferred stock, and stockholders' deficit, and cash flows for the year then ended show a net loss of $Y.
• The consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025, and the results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles.GNI Group Ltd. (Tokyo Stock Exchange: 2160) has released its FY2024 consolidated financial results, revealing a mixed performance across its operations. Revenue for the year declined by 9.2% to ¥23.6 billion, while operating profit plummeted by 89.3% to ¥1.4 billion. Pre-tax profit also fell sharply by 98.1% to ¥238 million, and the company reported a net loss of ¥130 million for the year. Basic earnings per share dropped from ¥169.50 in FY2023 to ¥19.55 in FY2024, reflecting <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm">increased expenses and challenging environment</a>.Despite the decline in profitability, the company’s total assets increased by 8.8% to ¥69.9 billion as of December 31, 2024, driven by growth in non-current intangible assets. Total liabilities rose by 9.0% to ¥30.2 billion, primarily due to higher short-term borrowings. Total equity also increased by 8.7% to ¥39.6 billion, supported by <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm">other components of equity</a>.Operating cash flow turned negative in FY2024, with a cash outflow of ¥3.1 billion, compared to a ¥6.5 billion inflow in FY2023. This was largely due to increased corporate income tax payments. Meanwhile, investing activities saw a cash outflow of ¥10.3 billion, driven by leasehold deposits and securities purchases. Financing activities generated a modest cash inflow of ¥694 million, primarily from <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm">short-term borrowings and capital contributions</a>.The company’s pharmaceutical segment, which includes its subsidiary Gyre Pharmaceuticals, reported a 20.3% decline in revenue to ¥18.3 billion. Segment profit fell by 96.9% to ¥300 million, although this was partially offset by the absence of one-time gains recorded in FY2023. The medical device segment, however, saw a 73.5% increase in revenue to ¥5.3 billion, although <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm">segment profit declined slightly by 4.7%</a>.Research and development expenses increased by 9.9% to ¥2.8 billion, reflecting ongoing clinical trials and drug development efforts at Cullgen. Selling, general, and administrative expenses rose by 3.1% to ¥15.7 billion, reflecting <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm">increased SG&amp;A expenses</a>.Looking ahead, GNI Group has provided earnings forecasts for FY2025, projecting revenue of ¥28.7 billion and operating profit of ¥23.2 billion. The company expects to see continued progress in its pharmaceutical and biotechnology initiatives, including <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm">expansion of drug portfolio</a>.The consolidated financial statements for FY2024 were prepared in accordance with International Financial Reporting Standards (IFRS) and present <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036125004957/ny20043721x1_ex99-1.htm">fair view of financial position</a>.

GYRE News